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Crystal Engineering of Nutraceutical Phytosterols: New 
Cocrystal Solid-Solutions  
Rafael Barbas,a Lídia Bofill,b Dafne de Sande,a Mercè Font-Bardia,c and Rafel Prohens*a 
A  cocrystal  screening  conducted  with  a  solid  solution  of  three 
phytosterols (‐sitosterol, campesterol and stigmasterol)  and  a 
set  of  coformers with  strong hydrogen bond donors  reveals  that 
multicomponent solid‐solutions are preferentially formed instead 
of  pure  cocrystals  and  much  enriched  with  ‐sitosterol  with 
respect  to  stigmasterol,  a  natural  product  with  cytotoxicity 
concerns. 
 
Phytosterols are plant steroids with a structure similar to 
cholesterol. Their structures vary only in the carbon side chains 
and/or the presence or absence of a double bond (e.g. sitosterol 
and sitostanol). Phytosterols are widely distributed in the plant 
kingdom and specially found in vegetable oil, nuts, seeds and 
avocados. However, they are not synthesized by the human 
body and therefore their presence in the body is the result of 
their consumption as part of the diet. Particularly, the β-
Sitosterol is the most common dietary phytosterol.1 Several 
clinical studies have demonstrated that phytosterols reduce 
serum cholesterol levels by inhibiting cholesterol absorption in 
the intestinal lumen.2 Particularly, beta-sitosterol is useful for 
the reduction of serum total and LDL-cholesterol levels because 
the beta-sitosterol competes with cholesterol for up taking the 
cholesterol by the cells or by interfering with the esterification 
of cholesterol. In fact, beta-sitosterol has been approved by the 
FDA (Food and drug Administration) for that indication.3 
Moreover, Phytosterol-induced treatment sensitivity has been 
studied with multidrug resistance in cancer therapy. Recently β-
sitosterol, has shown to have an effect in drug-resistant 
colorectal cancer cells by inhibiting breast cancer resistance 
protein expression.4 It is known that different solid forms of an 
active ingredient can have different properties, and offer certain 
advantages with regard to solubility or bioavailability. Thus, the 
discovery of new solid forms allows for improving the 
pharmacokinetic and/or pharmacologic or other 
physicochemical properties of the active ingredients. In recent 
years cocrystal formation has emerged as a viable strategy 
towards improving the pharmacokinetic data of active 
ingredients.5 One of the main issues is to select the appropriated 
pharmaceutical acceptable coformers which can interact 
satisfactorily with the active ingredient and, at the same time, 
provide to the new entity with advantageous physicochemical 
properties, like bioavailability or stability .6    
Impurities in the raw material may significantly impact 
crystallization process giving rise a new crystal forms, either 
stables or metastables7 or can reduce the nucleation rate.8 A 
particular case is the study of a multicomponent crystal      of 
variable stoichiometry in which the impurity is a compound 
whose structure and size is similar to the main compound in the 
crystal lattice. This kind of compounds are called 
nonstoichiometric substitutional mixed crystals (or crystalline 
solid solutions), (CSS).9 
CSS have attracted interest in the past decade among 
crystallographers,10-11 mainly because they have the potential to 
design tunable materials for pharmaceutical applications, which 
makes solid solutions relevant in the scope of crystal 
engineering.12-13 However, these solid forms are not well 
understood yet and are difficult to obtain.14 Since the solid state 
of CSS is scarcely studied with respect to pharmaceutical and 
nutraceutical compounds not much is known about how the 
formation of CSS can impact the physicochemical properties of 
the crystal form. For instance, the difficulty to identify the 
number of molecules in the asymmetric unit, especially in 
chiral compounds, as a racemic solid solution of enantiomers15-
17 or a mixture of two diastereomers.18 In this sense, a good 
approach to identify potential CSS formers is by taking 
advantage of the isostructurality and isomorphicity concepts19-21 
but at present it is difficult to determine whether two or more 
molecules will be completely miscible in the crystal structure as 
well as their random distribution in the crystal lattice. 
In this work, we aimed to extend the solid-state knowledge of 
the important nutraceutical β-sitosterol by engineering new 
cocrystals. And       for the first time new multicomponent 
forms of      β-sitosterol       containing other phytosterols in the 
crystal lattice are reported. The new cocrystals, in form of CSS, 
have been discovered through an experimental cocrystal 
screening by using a broad set of thermodynamic and kinetic 
experimental conditions. 
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Figure 1. Molecular structures of sterols. Aliphatic chain 
differences are present from C19 (Rn schematic representation)  
 
Since commercial sources of β-sitosterol at affordable prices 
are usually mixtures of phytosterols in the form of solid 
solutions,22 we decided to conduct the study with such mixture, 
in the form of a ternary solid solution containing campesterol 
and stigmasterol as the starting material. Thus, we have 
performed a comprehensive cocrystal screen with a set of 
coformers, which includes carboxylic acids and phenol-
containing compounds from a variety of 30 organic solvents, 
which produced 370 crystalline solids (see ESI, for 
experimental and characterization details).  
Nine multicomponent forms of β-sitosterol (SIT) with different 
proportion of phytosterols (SIT CSS) (one solvate and eight 
cocrystals) have been obtained through a cocrystal screening 
with five out of the twenty-seven coformers tested. One solvate 
form with benzyl alcohol (BzOH) in a 4:1 molar ratio (as a 
tetartohydrate form, SIT-BzOH-H2O). Eight SIT CSS have 
been obtained with five coformers: three forms with propionic 
acid (ProA) in two different stoichiometries: one in a 2:1 molar 
ratio (as a hemihydrate form, SIT-ProA-H2O I) and two in a 4:1 
molar ratio (as an tetartohydrate form, SIT-ProA-H2O II and as 
an acetonitrile tetartosolvate form SIT-ProA-ACN); one form 
with zymonic acid (ZA) in a 2:1 stoichiometry (as an 
hemihydrate form, SIL-ZA-H2O); one form with gallic acid 
(GA) in a 4:1 stoichiometry (as an anhydrous form, SIL-GA); 
two with 4-hydroxybenzoic acid (4-HBA) in a 1:1 
stoichiometry (one as an anhydrous form, SIT-4-HBA I and one 
as a hemihydrate form, SIT-4-HBA-H2O II) and finally one 
with 3,4-dihydroxybenzoic acid (3,4-DHBA) in a 1:2 
stoichiometry (as a monohydrate, SIT-3,4-DHBA-H2O). Since 
our raw material is a CSS of three phytosterols, accurate 
determination of each phytosterol content is essential for the 
intellectual property implications and the full characterization 
of the new forms. In this sense, the phytosterols present in all 
new CSS forms were quantified and the content of each 
phytosterol determined using GC and HPLC techniques. The 
details about GC and HPLC methods are provided in ESI.   
Quantification shows that in average β-sitosterol (⁓ 86%) is in 
higher proportion followed by campesterol (⁓ 9%) and 
stigmasterol (⁓ 5%), respectively. (Table 1) 
Experiments conducted with propionic acid as the coformer 
produced three different cocrystal forms with two different 
stoichiometries, according to NMR and SCXRD measurements. 
In particular, experiments conducted generally through kinetic 
control conditions produced a 2:1 cocrystal solid solution (for 
instance, use of water as an antisolvent in the precipitation of a 
solution of the phytosterols solid solution in propionic acid), 
while thermodynamic control experiments, produced a 4:1 
cocrystal solid solution (for instance, slurry experiment for one 
day in propionic acid-acetone suspension). While NMR 
experiments could not confirm the presence of water Single X-
ray Diffraction measurements allowed to not only confirm the 
stoichiometry but also determine the presence of a molecule of 
water in the crystal lattice, being new forms SIT-ProA-H2O I 
and SIT-ProA-H2O II 2:1:1 and 4:1:1 SIT CSS:propionic 
acid:water Cocrystal Solid Solution hydrates, respectively. The 
last crystal form is an ACN solvate with 4:1:1 stoichiometry 
confirmed by SCXRD and it was obtained by ACN atmosphere 
diffusion through SIT CSS-propionic acid acetone solution 
(SIT-ProA-ACN).  
Unfortunately, the low proportion of two phytosterols 
(stigmasterol and campesterol) together with the low quality of 
the single crystals and the presence of substitutional disorder 
(deduced from the large size of the ellipsoids associated to the 
carbon atoms at the end of the aliphatic chains) due to the 
presence of the three phytosterols make difficult to determine 
the crystal structures with precision. Thus, we have refined 
them considering that all the molecules present in the lattice are 
β-sitosterol. However, these data are still valuable for the 
purposes of characterization of the new cocrystals.  
Table 1. HPLC quantification of the different phytosterols in the standard sample and new CSS 
Crystal form 
Stigmasterol Campesterol β-Sitosterol  
RTa (min) Areab (%) RT (min) Area (%) RT (min) Area (%) 
β-sitosterol standard (72.5%) 6.443 10.75 7.933 19.6 9.267 70.19 
CSS SIT-ProA-H2O I 6.256 7.09 7.777 9.76 9.167 83.14 
CSS SIT-ProA-H2O II 6.267 3.70 7.800 9.55 9.200 86.75 
CSS SIT-ZA-H2O 6.133 7.33 7.700 9.35 9.067 84.32 
CSS SIT-GA 6.367 5.51 7.822 9.38 9.222 85.11 
CSS SIT-4-HBA I 6.252 3.59 7.733 9.06 9.100 87.35 
CSS SIT-4-HBA-H2O II 6.250 6.03 7.767 9.16 9.167 84.82 
CSS SIT-3,4-DHBA-H2O 6.284 5.45 7.767 9.27 9.167 85.27 
Standard deviation (SD)c 6.262±0.064 5.22±1.64 7.760±0.041 9.27±0.34 9.147±0.056 85.64±1.71 
a: “RT” means retention time; b: The area is expressed in percentage (W/W); c: Average of all the cocrystals 
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Net grinding experiments conducted with pyruvic acid as the 
coformer and SIT CSS, produced a new cocrystal with a 
different coformer in the crystal lattice as a consequence of an 
in situ chemical reaction in solution which transformed pyruvic 
acid in zymonic acid. This transformation has been previously 
reported in literature.23 Moreover, experiments conducted with 
pyruvic acid containing 7% of zymonic acid (determined by 
NMR) as the coformer (solvent-mediated transformation in 
cyclohexane at 25 °C for four days) produced a 2:1:1 zymonic 
acid cocrystal solid solution. No evidences of pyruvic acid 
cocrystal solid solution has been observed. In a similar way as 
with propionic acid cocrystals, low quality crystal structure 
determination confirmed the presence of water with a 2:1:1 
stoichiometry. Interestingly, comparative cell parameters 
suggest that it corresponds to a zymonic acid solid solution 
different from the bulk powder. 
Solvent-mediated transformation experiments between SIT 
CSS and gallic acid in AcOEt at 25 °C for one day produced an 
anhydrous 4:1 gallic acid cocrystal solid solution (SIT-GA). As 
previously described, low quality crystal structure 
determination confirmed a 4:1 stoichiometry. 
Experiments conducted with 4-hydroxybenzoic acid as a 
coformer produced two different cocrystal forms, one 
anhydrous and one hemihydrate with the same stoichiometry, 
according to NMR and TGA measurements. In particular, 
solvent-mediated transformation experiments between SIT CSS 
and 4-hydroxybenzoic acid (in a molar ratio 1:1.1) in AcOEt at 
25 °C for two days produced an anhydrous 1:1 4-
hydroxybenzoic acid cocrystal solid solution (SIT-4-HBA I). 
On the other hand, reaction crystallization experiments with the 
coformer saturated in AcOEt at 25 °C for one day produced a 
hemihydrate 2:2:1 4-hydroxybenzoic acid cocrystal solid 
solution (SIT-4-HBA-H2O II). 
Reaction crystallization experiments conducted with 3,4-
dihydroxybenzoic acid as the coformer saturated in AcOEt at 
25 °C for one day produced a monohydrate 1:2:1 3,4-
dihydroxybenzoic acid cocrystal solid solution (SIT-3,4-
DHBA-H2O).  
As said before, although great efforts were devoted to produce 
good quality single crystals of all the new CSS forms, in all 
cases thin needles were obtained. Five crystal structures have 
been determined but, unfortunately, as a consequence of 
problems derived from poor data, the refinement can be used 
mainly to estimate their stoichiometry. On the other hand, high-
resolution PXRD diffractograms of the new forms were 
indexed and the lattice parameters were refined by means of 
LeBail fits by using Dicvol04 software.24 Indexed cell 
parameters were compared with the single crystal analysis to 
confirm that the single crystals and the bulk powders 
correspond to the same solid forms. Comparative 
crystallographic data and refinement details of CSS form are 
shown in Table 2.    
In absence of good quality SCXRD data it is not possible to 
analyze with precision the structural features of the new 
multicomponent solid forms and, in fact it is not the subject of 
this paper although another future research is intended to focus 
on that particular issue. We think that for the purposes of this 
paper it is more important to discuss on the proportion of 
phytosterols in the new cocrystals. Thus, the most important 
common feature of all the cocrystals is that the coformer, as 
expected, is inserted forming layers between the alcohol 
moieties of each sterol solid solution. Interestingly, the 
resulting CSS are enriched with β-sitosterol and with a variable 
and low proportion of stigmasterol and campesterol. The lower 
proportion of stigmasterol with respect to the other phytosterols 
in the solid solution is probably due to the different flexibility 
of the aliphatic chain. Stigmasterol, in contrast to β-sitosterol 
and campesterol has a double bond in carbon 19, which 
increases its conformational rigidity at the end of the chain and 
probably fits worst with the other phytosterols in the crystal 
lattice. However, this proportion is variable depending on the 
coformer present in the CSS and the experimental conditions of 
Table 2. Crystallographic data and refinement details of β-sitosterol crystalline solid solution: R-factor for SCXRD and Rwp for PXRD  





PXRD 38.21(3) 9.935(2) 7.640(2) 88.48(1) 93.38(3) 96.34(4) 2877(2) 1 298 P1 9.62 
SCXRD 37.763(14) 9.730(4) 7.597(3) 84.846(9) 86.089(8) 88.219(9) 2772.8(19) 1 100 P1 4.61 
SIT-ProA-H2O I 
PXRD 40.0(2) 7.617(2) 9.631(1) 90 97.03(3) 90 2914(2) 2 298 P21 6.88 
SCXRD 39.635(8) 7.5391(16) 9.439(2) 90 95.216(6) 90 2808.8(10) 2 293 P21 4.46 
SIT-ProA-H2O II 
PXRD 28.16(1) 7.568(2) 26.235(9) 90 92.09(2) 90 5587(3) 2 298 P21 11.5 
SCXRD 27.183(3) 7.4971(7) 26.373(3) 90 92.569(6) 90 5369.2(10) 2 100 P21 10.1 
SIT-ProA-ACN SCXRD 36.973(9) 9.702(3) 7.581(2) 82.962(5) 86.112(5) 89.740(5) 2692.7(13) 1 100 P1 10.6 
SIT-ZA-H2O 
PXRD 39.51(2) 6.982(3) 20.126(7) 90 95.18(4) 90 5528(4) 4 298 P21 10.1 
SCXRD 77.42(2) 7.6086(18) 9.924(3) 90 90.948(7) 90 5845(3) 4 293 C2 6.02 
SIT-GA 
PXRD 38.54(5) 13.812(4) 10.882(3) 90 92.33(5) 90 5788(8) 2 298 P21 11.1 
SCXRD 38.1228(19) 13.6989(6) 10.7439(5) 90 93.002(2) 90 5603.2(5) 2 100 P21 8.97 
SIT-4-HBA I  PXRD 38.16(5) 14.196(6) 10.549(4) 90 92.0(1) 90 5711(8) 8 298 P21 21.3 
SIT-4-HBA-H2O II PXRD 42.87(3) 7.083(5) 8.361(5) 107.3 (1) 108.8(1) 89.06(3) 2285(3) 3 298 P-1 7.21 
SIT-3,4-HBA-H2O PXRD 38.91(4) 14.017(8) 10.701(5) 90 92.41(9) 90 5832(8) 6 298 P21 22.6 
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production. For instance, depending on the conditions 4-HBA 
produces two different CSS with different distribution of 
phytosterols. Moreover, form I is the one with the lowest 
amount of stigmasterol (only 3.59%) and the highest amount of 
β-sitosterol. For comparison reasons we determined the content 
of the three phytosterols present in a commercial analytical 
standard, which contains 10.75% of stigmasterol. These results 
show that in principle it is possible to modify the content of a 
particular phytosterol in the solid by changing the experimental 
conditions. 
Although relevant progress has been achieved in the production 
of some phytosterols in pure form, the extraction and 
purification techniques are still complicated and time-
consuming, particularly with high costs when large amounts of 
pure sterols are required.25,26 Furthermore, the origin of the 
natural sources affects to the final compositions of phytosterols. 
But in general terms the simplest isolation approach based on 
crystallizations can produce β-sitosterol with purity in the 70% 
range. Further purification to >90% purity can be achieved with 
expensive chromatographic techniques.27 In this sense, our 
results can be particularly advantageous from an industrial 
point of view since it has been recently reported that 
stigmasterol accumulation can cause cardiac injury and 
promote mortality.28 As said before, current clinical strategies 
are designed to reduce the levels of cholesterol by consuming 
diets rich in phytosterols. However, in the form of a 
nutraceutical formulation a mixture of phytosterols can have a 
significant percentage of stigmasterol (as in our starting 
material), which can represent a potential risk factor for heart 
disease by inducing cardiac fibrosis. Particularly, individuals 
suffering of the rare illness called sitosterolemia (defects in 
their phytosterol absorption process) are more prone to be 
affected by high levels of stigmasterol.29 Cocrystal Solid 
Solutions with a reduced level of stigmasterol can represent a 
new research line to develop efficient phytosterol formulations 
richer in β-sitosterol and depleted in stigmasterol suitable for 
clinical cardiovascular applications.   
Conclusions 
Multicomponent molecular crystals of more than three 
components are a challenge, which Desiraju has approached 
successfully by crystal engineering with up to six 
components.30,31 Here, we have conducted a cocrystal screening 
between a phytosterol solid solution containing ‐sitosterol, 
campesterol  and  stigmasterol  and  a  series  of  coformers,  which 
include  carboxylic  acids  and phenolic  compounds.  8 new cocrystal 
solid  solutions  containing  four  different  compounds  have  been 
discovered  and  characterized.  The  discovered  CSS  are  a  new 
example of this poorly studied family of solid forms and show a low 
and  variable  proportion  of  stigmasterol with  respect  to  the  other 
two phytosterols, which can provide a valid strategy to formulate ‐
sitosterol  in  the  form  of  a  multicomponent  solid  solution  with 
reduced amounts of stigmasterol, a product with toxicity concerns. 
Further studies are being conducted to study the 
physicochemical properties and the effects of our new solid 
forms in vivo. 
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